HTI-3 revises information-blocking exceptions around reproductive-health information
The final rule changes the Privacy and Infeasibility Exceptions and adds a Protecting Care Access Exception, requiring policy and workflow review beyond technical exchange settings.
Editorial figure by Health Interoperability Review. Source context: ASTP/Office of the National Coordinator for Health IT.
Exchange controls must follow policy decisions
Platforms route, match, segment, transform, and log data, but an organization must first determine the legal and policy basis for acting on a request. HTI-3 changes part of that decision environment for actors subject to the information-blocking regulations.
Operational review should cover request intake, purpose, identity, data scope, applicable exception, documentation, escalation, response, and audit evidence. A blanket configuration applied to every channel is unlikely to capture the distinctions.
Product claims need an advice boundary
Consent and segmentation products can enforce configured policies and produce records, but they cannot make a disclosure decision without organization-specific facts and accountable review. Directories should describe technical functions without declaring that a tool makes an organization compliant.
Buyers should ask how policies are represented, updated, tested, explained, and overridden; which data can be segmented; how downstream limitations are disclosed; and what evidence remains when an exception is invoked.
Enterprise buyer test
Translate this change into the exact population, record type, workflow stage, decision owner, effective date, and evidence that could be affected. Ask current or prospective providers to demonstrate the named workflow with representative data and an exception—not a polished feature tour. Record what official documentation establishes, what a provider states, what the team observes, and what remains unresolved.
A defensible review also identifies the dependency outside the product. Authority interpretation, policy configuration, data quality, integrations, human judgment, approval rights, release governance, training, and retained evidence may remain customer or service responsibilities. The evaluation should preserve those boundaries instead of treating a technology claim as the complete operating model.
What we will watch next
Health Interoperability Review will watch the named source and affected market records for later evidence that changes status, scope, availability, implementation timing, workflow consequence, or the limits of the initial report. A later announcement does not silently overwrite this dated account; the change ledger preserves the sequence.